Ribocure Pharmaceuticals AB establishes in GoCo Clinic

Ribocure Pharmaceuticals AB establishes in GoCo Clinic- putting Sweden in the spotlight within oligonucleotide therapeutics

GoCo Health Innovation City can now happily announce that Ribocure Pharmaceuticals AB will move in and open a clinical trial unit at GoCo Clinic – where both patient care and research will be conducted. The ambitions are high and with the hope that the establishment will pave the way for the goal of becoming a European leader in RNA therapy. GoCo Clinic will be ready in the spring of 2023.

GoCo Active, GoCare, GoCo Living, GoCo House – and GoCo Clinic. The new district GoCo Health Innovation City continue investments with a majority of initiatives driving Swedish health innovation and life science into the future. The interest from both the industry, the business sector and the society has been enormous since the first sod was taken. Several residents are now ready to move in as buildings and development work are being completed. One of these is Ribocure Pharmaceuticals, which develops precision medicine through small interfering RNA (siRNA). Briefly described, it is about being able to turn off specific disease-causing genes and thereby cure both more uncommon genetic diseases as well as common diseases such as high blood pressure and high blood fats, etc.

– Our ambition is to put Sweden in the spotlight within oligonucleotid therapy and to conduct global clinical development here in Mölndal. At GoCo Clinic, we will conduct innovative proof of principle phase 1B and 2 studies and at the same time drive global product and business development, all on the same floor. So far, we have succeeded to reduce the development time from 8 years to less than 2 years in terms of going from idea to patient. I only see opportunities with the establishment at GoCo Clinic, from here we can become one of the leading companies in Europe, says Li-Ming Gan, CEO and Chief Medical Officer at Ribocure Pharmaceuticals AB.

The establishment is strategically important for the area as a whole and is welcomed by Jonas Obert, Business Developer at GoCo Health Innovation City.

– Ribocure Pharmaceuticals AB is an incredibly exciting company that will bring a lot of value to the area and not least – to the outside world in general. The basic idea for GoCo Health Innovation City is based on finding new paths to innovation and companies like Ribocure Pharmaceuticals AB can make this possible by bringing both knowledge and ambitions creating synergy effects throughout our community.

Find the full press release here.

Share on social media

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
E-mail: dpo@ribocure.com